Picard Medical (PMI.US), a Tucson-based medical device innovator, unveiled terms for its initial public offering on Monday. The company aims to sell 4.3 million ordinary shares priced between $3.50 and $4.50 apiece, targeting gross proceeds of approximately $17 million. Should pricing settle at the midpoint, Picard's fully diluted valuation would reach $320 million. Trading under the ticker "PMI," the Arizona firm has formally submitted its IPO application to U.S. securities regulators.

Holding a unique position as the globe's sole provider of implantable total artificial hearts cleared by both the U.S. FDA and Health Canada, Picard operates through its SynCardia brand. The flagship SynCardia TAH device serves critically ill patients suffering biventricular failure, functioning as a bridge-to-transplant solution. This pioneering technology has already facilitated over 2,100 life-saving implant procedures across 27 countries. By completely replacing the native heart's pumping action, the system grants end-stage heart failure patients vital extra time while awaiting donor organs.

Financial disclosures reveal Picard generated $3 million in revenue during the twelve months ending March 31, 2025. Tracing its origins to 1985, this nearly four-decade-old medtech enterprise now seeks public market entry. WestPark Capital, Uphorizon, and Sentinel Brokers will jointly manage the offering as co-bookrunners, overseeing share distribution and final pricing.

Proceeds will primarily fuel expansion of Picard's product pipeline, enhance market access capabilities, and support upcoming clinical trials. With the global population of heart failure patients swelling steadily, SynCardia TAH’s status as the only commercially available total artificial heart positions the company to capitalize on its market exclusivity through this capital infusion.